CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...